Myxoid liposarcoma is a cancerous tumor that develops from fat cells, most often in the deep soft tissues of the thigh, buttocks, or trunk. It accounts for roughly 20 to 30 percent of all liposarcomas, making it one of the more common subtypes of this already rare cancer. It typically appears in younger adults between the ages of 30 and 50, and its behavior and outlook depend heavily on what the tumor looks like under a microscope.
Where It Develops and How It Presents
The thigh is the single most common location for myxoid liposarcoma, followed by the buttocks, retroperitoneum (the space behind the abdominal organs), trunk, and the area around the hip and shoulder. It grows in deep soft tissue, often surrounded by muscle, and can reach a significant size before causing noticeable symptoms. Most people first notice a painless, slowly enlarging lump. Because it tends to grow quietly, it may be present for months or even years before diagnosis.
What Drives the Cancer
More than 90 percent of myxoid liposarcomas are driven by a single genetic event: a swap of material between chromosomes 12 and 16. This rearrangement fuses two genes together, creating an abnormal protein that pushes immature fat cells to multiply uncontrollably. This fusion is so specific to myxoid liposarcoma that testing for it is one of the most reliable ways to confirm the diagnosis. Unlike many cancers that accumulate dozens of mutations over time, myxoid liposarcoma is essentially a “one-hit” disease, defined by this translocation.
How It Looks on Imaging
On MRI, myxoid liposarcoma has a distinctive appearance that can sometimes be spotted even before a biopsy. The tumor typically appears as a predominantly dark mass on certain MRI sequences, with scattered bright streaks or patches representing small amounts of fat woven through the tissue. About 70 percent of tumors show this lacy pattern of fat signal within an otherwise low-signal mass. This combination is unusual enough to raise suspicion for myxoid liposarcoma specifically, even when the mass otherwise looks benign.
Low-Grade vs. High-Grade Tumors
Not all myxoid liposarcomas behave the same way. The critical factor is how much of the tumor contains densely packed, round cells versus the looser, jelly-like (myxoid) tissue that gives the cancer its name.
Tumors with more than 5 percent round cell content carry a significantly worse prognosis. In one large analysis, patients with greater than 5 percent round cells saw their overall survival drop from about 92 percent at two years to just 50 percent at ten years. Those with more than 25 percent round cells had a five-year metastasis-free survival of only 69 percent. By contrast, pure myxoid tumors with minimal round cell content have a five-year survival rate around 90 percent and a ten-year rate of about 83 percent.
Other factors linked to a worse outcome include tumors larger than 15 centimeters, location deep within the body, and surgical margins that aren’t completely clear of cancer.
An Unusual Pattern of Spread
One of the most distinctive features of myxoid liposarcoma is where it spreads when it metastasizes. Most soft tissue sarcomas send metastases to the lungs first. Myxoid liposarcoma does the opposite. It tends to spread to other soft tissue sites, the retroperitoneum, the chest wall, the opposite limb, and bone before it ever reaches the lungs. This means standard surveillance strategies designed to catch lung metastases may miss spread in this particular cancer. Doctors who specialize in sarcoma typically recommend whole-body imaging, including scans of the spine and abdomen, rather than chest imaging alone.
Surgery and Radiation
The primary treatment for localized myxoid liposarcoma is surgery to remove the entire tumor with a margin of healthy tissue around it. The goal is achieving what surgeons call “negative margins,” meaning no cancer cells at the cut edge. This can be challenging because the tumor often infiltrates surrounding tissue, particularly when it’s large or buried deep in muscle.
Radiation therapy before surgery has become the standard approach at many cancer centers. Preoperative radiation shrinks the tumor, making it easier to remove completely and reducing the chance of local recurrence. It’s also associated with better overall survival by limiting tumor growth and lowering the risk of metastasis. When surgery can’t achieve clean margins, radiation after surgery is used instead, typically at higher doses, to reduce the risk of the cancer returning at the original site.
Systemic Treatment Options
Myxoid liposarcoma is notably more sensitive to certain systemic treatments than other soft tissue sarcomas. One drug, trabectedin, has shown particular effectiveness against this subtype. In a study of patients with localized, resectable tumors treated with trabectedin combined with radiation before surgery, 83 percent showed a meaningful response by imaging criteria that measure changes in tumor density. When pathologists examined the removed tumors, 13 percent had no remaining viable cancer, and 51 percent had 10 percent or less cancer remaining. Trabectedin has also been used alone before surgery, producing similar complete pathologic response rates with additional treatment cycles.
This sensitivity to trabectedin appears to be linked to the specific genetic translocation that defines the disease, making it one of the few sarcomas where a targeted systemic option exists for patients who need more than surgery and radiation.
Long-Term Outlook
For the majority of patients with pure or predominantly myxoid tumors, the long-term outlook is favorable compared to many other sarcomas. The five-year disease-specific survival is approximately 90 percent, and the ten-year rate holds at about 83 percent. Disease-free survival, meaning no recurrence or spread, reaches 77 percent at both five and ten years, suggesting that patients who remain free of disease at the five-year mark are unlikely to relapse later.
Round cell liposarcoma, the high-grade end of the spectrum, carries a meaningfully different prognosis. Studies have reported 10- to 12-year survival rates ranging from 53 to 82 percent depending on the proportion of round cells present. Because prognosis varies so dramatically based on histology, an accurate pathology review by a sarcoma specialist is one of the most important steps in guiding treatment decisions.